Business
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced a partnership with Qureight, a Core Imaging Laboratory developing deep-learning image analytics, to enhance the outcome and output of data from Cumberland's FIGHTING FIBROSIS™ clinical trial. The Phase II study is evaluating Cumberland's ifetroban product candidate in patients with idiopathic pulmonary fibrosis (IPF), the most comm
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial","length":119,"tagName":"p","attribs":{}},{"type":"text","content":"NASHVILLE, Tenn. and CAMBRIDGE, England, May 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced a partnership with Qureight, a Core Imaging Laboratory developing deep-learning image analytics, to enhance the outcome and output of data from Cumberland's FIGHTING FIBROSIS™ clinical trial. The Phase II study is evaluating Cumberland's ifetroban product candidate in patients with idiopathic pulmonary fibrosis (IPF), the most common form of progressive fibrosing interstitial lung disease. This collaboration aims to address a critical unmet need for the estimated 2 million IPF patients worldwide, who currently have limited treatment options that can effectively halt disease progression. The partnership will utilize Qureight's advanced, deep-learning image analytics tools for complex lung disease applications to provide deeper insights into treatment efficacy and disease progression in Cumberland's IPF clinical program.","length":1093,"tagName":"p"},{"type":"image","alt":"Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.)","displaySize":"","headline":null,"caption":"Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":85,"url":"https://media.zenfs.com/en/prnewswire.com/3afebe83ec3d4bc266a4bcc9278af913"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/W65H8Am_Z_mSA2sDK0ostg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3afebe83ec3d4bc266a4bcc9278af913","width":400,"height":85}},"href":"https://mma.prnewswire.com/media/84325/Cumberland_Pharmaceuticals_logo_new1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under this partnership, Qureight's AI-driven analytics technologies will be used to quantify changes in multiple imaging biomarkers, using computed tomography (CT) data from FIGHTING FIBROSIS™ study patients. Qureight's quantitative deep learning-based tools will precisely m...